SCHEMBL454130

SCHEMBL454130

COC(=O)CCCCCCCCCBr

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.67
LMNA P02545 3/20 0.57
ALDH1A1 P00352 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.49
KMT2A Q03164 3/20 0.47
RECQL P46063 1/20 0.46
EPHX2 P34913 2/20 0.43
MEN1 O00255 2/20 0.43
POLB P06746 1/20 0.42
POLA1 P09884 1/20 0.42
HPGD P15428 1/20 0.42
CA12 O43570 1/20 0.41
CA14 Q9ULX7 1/20 0.41
DGKA P23743 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31049868 1.00 TSHR (0.67) TSHRLMNAALDH1A1L3MBTL1KMT2A
SCHEMBL4006166 1.00 TSHR (0.67) TSHRLMNAALDH1A1L3MBTL1KMT2A
SCHEMBL1365242 1.00 TSHR (0.67) TSHRLMNAALDH1A1L3MBTL1KMT2A
SCHEMBL11849992 1.00 TSHR (0.67) TSHRLMNAALDH1A1L3MBTL1KMT2A
SCHEMBL16719251 1.00 TSHR (0.67) TSHRLMNAALDH1A1L3MBTL1KMT2A
SCHEMBL1115015 1.00 TSHR (0.67) TSHRLMNAALDH1A1L3MBTL1KMT2A
SCHEMBL8973175 1.00 TSHR (0.67) TSHRLMNAALDH1A1L3MBTL1KMT2A
SCHEMBL1365853 1.00 TSHR (0.67) TSHRLMNAALDH1A1L3MBTL1KMT2A
SCHEMBL1285241 1.00 TSHR (0.67) TSHRLMNAALDH1A1L3MBTL1KMT2A
SCHEMBL31734806 1.00 TSHR (0.67) TSHRLMNAALDH1A1L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110724052-B Eugenol surfactant and application thereof 江南大学 2020-12-29 CN claimed
CN-110724052-A Eugenol surfactant and application thereof 江南大学 2020-01-24 CN claimed
EP-3532528-A1 RENEWABLY DERIVED POLYAMIDES AND METHODS OF MAKING THE SAME Elevance Renewable Sciences, Inc. (US) 2019-09-04 EP claimed
CN-109843976-A The polyamide and its manufacturing method obtained by renewable source 埃莱万斯可再生能源科学股份有限公司 2019-06-04 CN claimed
WO-2018080869-A1 RENEWABLY DERIVED POLYAMIDES AND METHODS OF MAKING THE SAME ELEVANCE RENEWABLE SCIENCES, INC. (US) 2018-05-03 WO claimed
CN-102350278-B Preparation of drug-carrying chitosan microspheres UNIV BEIJING CHEMICAL 2013-06-12 CN claimed
CN-102350278-A Preparation of drug-carrying chitosan microspheres UNIV BEIJING CHEMICAL 2012-02-15 CN claimed
CN-1580036-A Method for synthesizing 10-P-nitrobenz-oxy-capric acid UNIV ZHEJIANG (CN) 2005-02-16 CN claimed
CN-1580032-A Method for synthesizing 10-bromo methyl caprate UNIV ZHEJIANG (CN) 2005-02-16 CN claimed
US-5908723-A Recording sheets XEROX CORPORATION (US) 1999-06-01 US claimed
CN-122055150-A Cyproheptadine derivatives 思凯生科股份有限公司 2026-05-15 CN disclosed
US-20250361250-A1 FLUORINE-CONTAINING SILANE COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2025-11-27 US disclosed
US-20250288683-A1 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS Treeline Biosciences, Inc. 2025-09-18 US disclosed
EP-4608876-A2 ENDOCYTIC AGENTS BioVentures, LLC (US) 2025-09-03 EP disclosed
EP-4569012-A1 EFFICIENT SYNTHESIS OF VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS University of Utah Research Foundation (US) 2025-06-18 EP disclosed
EP-0190042-B1 ORGANIC COMPOUNDS AND THEIR PHARMACEUTICAL USE Lilly Industries Limited (GB) 1991-10-30 EP disclosed
US-4997847-A Thromboxane A2 antagonists SMITH KLINE & FRENCH LABORATORIES LIMITED (DE) 1991-03-05 US disclosed
EP-0304271-A2 Omega-arylsulphonamidoalkanoic acids for treatment of thromboxane medited diseases SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1989-02-22 EP disclosed
US-4675335-A LEUKOTRIENE ANTAGONISTS LILLY INDUSTRIES LIMITED (GB) 1987-06-23 US disclosed
EP-0190042-A2 Organic compounds and their pharmaceutical use Lilly Industries Limited (GB) 1986-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250361250-A1 FLUORINE-CONTAINING SILANE COMPOUND FLI1, AFF1, RFT1 TSHR 2035/4885LMNA 1768/4885ALDH1A1 879/4885
US-20250288683-A1 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS BCL2L1, BCL2, BCL2L10 TSHR 3777/4885LMNA 3184/4885ALDH1A1 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.